Reducing  ||| S:0 E:9 ||| VBG
confounding  ||| S:9 E:21 ||| NNS
and  ||| S:21 E:25 ||| CC
suppression  ||| S:25 E:37 ||| JJ
effects  ||| S:37 E:45 ||| NNS
in  ||| S:45 E:48 ||| IN
TCGA  ||| S:48 E:53 ||| NNP
data ||| S:53 E:57 ||| NNS
:  ||| S:57 E:59 ||| :
an  ||| S:59 E:62 ||| DT
integrated  ||| S:62 E:73 ||| JJ
analysis  ||| S:73 E:82 ||| NN
of  ||| S:82 E:85 ||| IN
chemotherapy  ||| S:85 E:98 ||| JJ
response  ||| S:98 E:107 ||| NN
in  ||| S:107 E:110 ||| IN
ovarian  ||| S:110 E:118 ||| JJ
cancer  ||| S:118 E:125 ||| NN
Despite  ||| S:125 E:133 ||| IN
initial  ||| S:133 E:141 ||| JJ
response  ||| S:141 E:150 ||| NN
in  ||| S:150 E:153 ||| IN
adjuvant  ||| S:153 E:162 ||| JJ
chemotherapy ||| S:162 E:174 ||| NN
,  ||| S:174 E:176 ||| ,
ovarian  ||| S:176 E:184 ||| JJ
cancer  ||| S:184 E:191 ||| NN
patients  ||| S:191 E:200 ||| NNS
treated  ||| S:200 E:208 ||| VBN
with  ||| S:208 E:213 ||| IN
the  ||| S:213 E:217 ||| DT
combination  ||| S:217 E:229 ||| NN
of  ||| S:229 E:232 ||| IN
paclitaxel  ||| S:232 E:243 ||| NN
and  ||| S:243 E:247 ||| CC
carboplatin  ||| S:247 E:259 ||| VBP
frequently  ||| S:259 E:270 ||| RB
suffer  ||| S:270 E:277 ||| VB
from  ||| S:277 E:282 ||| IN
recurrence  ||| S:282 E:293 ||| NN
after  ||| S:293 E:299 ||| IN
few  ||| S:299 E:303 ||| JJ
cycles  ||| S:303 E:310 ||| NNS
of  ||| S:310 E:313 ||| IN
treatment ||| S:313 E:322 ||| NN
,  ||| S:322 E:324 ||| ,
and  ||| S:324 E:328 ||| CC
the  ||| S:328 E:332 ||| DT
underlying  ||| S:332 E:343 ||| JJ
mechanisms  ||| S:343 E:354 ||| NNS
causing  ||| S:354 E:362 ||| VBG
the  ||| S:362 E:366 ||| DT
chemoresistance  ||| S:366 E:382 ||| NNS
remain  ||| S:382 E:389 ||| VBP
unclear ||| S:389 E:396 ||| JJ
.  ||| S:396 E:398 ||| .
Recently ||| S:398 E:406 ||| RB
,  ||| S:406 E:408 ||| ,
The  ||| S:408 E:412 ||| DT
Cancer  ||| S:412 E:419 ||| NNP
Genome  ||| S:419 E:426 ||| NNP
Atlas  ||| S:426 E:432 ||| NNP
( ||| S:432 E:433 ||| -LRB-
TCGA ||| S:433 E:437 ||| NNP
)  ||| S:437 E:439 ||| -RRB-
research  ||| S:439 E:448 ||| NN
network  ||| S:448 E:456 ||| NN
concluded  ||| S:456 E:466 ||| VBD
an  ||| S:466 E:469 ||| DT
ovarian  ||| S:469 E:477 ||| JJ
cancer  ||| S:477 E:484 ||| NN
study  ||| S:484 E:490 ||| NN
and  ||| S:490 E:494 ||| CC
released  ||| S:494 E:503 ||| VBN
the  ||| S:503 E:507 ||| DT
dataset  ||| S:507 E:515 ||| NN
to  ||| S:515 E:518 ||| TO
the  ||| S:518 E:522 ||| DT
public ||| S:522 E:528 ||| NN
.  ||| S:528 E:530 ||| .
The  ||| S:530 E:534 ||| DT
TCGA  ||| S:534 E:539 ||| NNP
dataset  ||| S:539 E:547 ||| NN
possesses  ||| S:547 E:557 ||| VBZ
large  ||| S:557 E:563 ||| JJ
sample  ||| S:563 E:570 ||| NN
size ||| S:570 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
comprehensive  ||| S:576 E:590 ||| JJ
molecular  ||| S:590 E:600 ||| JJ
profiles ||| S:600 E:608 ||| NNS
,  ||| S:608 E:610 ||| ,
and  ||| S:610 E:614 ||| CC
clinical  ||| S:614 E:623 ||| JJ
outcome  ||| S:623 E:631 ||| NN
information ||| S:631 E:642 ||| NN
;  ||| S:642 E:644 ||| :
however ||| S:644 E:651 ||| RB
,  ||| S:651 E:653 ||| ,
because  ||| S:653 E:661 ||| IN
of  ||| S:661 E:664 ||| IN
the  ||| S:664 E:668 ||| DT
unknown  ||| S:668 E:676 ||| JJ
molecular  ||| S:676 E:686 ||| JJ
subtypes  ||| S:686 E:695 ||| NN
in  ||| S:695 E:698 ||| IN
ovarian  ||| S:698 E:706 ||| JJ
cancer  ||| S:706 E:713 ||| NN
and  ||| S:713 E:717 ||| CC
the  ||| S:717 E:721 ||| DT
great  ||| S:721 E:727 ||| JJ
diversity  ||| S:727 E:737 ||| NN
of  ||| S:737 E:740 ||| IN
adjuvant  ||| S:740 E:749 ||| JJ
treatments  ||| S:749 E:760 ||| NNS
TCGA  ||| S:760 E:765 ||| JJ
patients  ||| S:765 E:774 ||| NNS
went  ||| S:774 E:779 ||| VBD
through ||| S:779 E:786 ||| RP
,  ||| S:786 E:788 ||| ,
studying  ||| S:788 E:797 ||| VBG
chemotherapeutic  ||| S:797 E:814 ||| JJ
response  ||| S:814 E:823 ||| NN
using  ||| S:823 E:829 ||| VBG
the  ||| S:829 E:833 ||| DT
TCGA  ||| S:833 E:838 ||| NNP
data  ||| S:838 E:843 ||| NN
is  ||| S:843 E:846 ||| VBZ
difficult ||| S:846 E:855 ||| JJ
.  ||| S:855 E:857 ||| .
Additionally ||| S:857 E:869 ||| RB
,  ||| S:869 E:871 ||| ,
factors  ||| S:871 E:879 ||| NNS
such  ||| S:879 E:884 ||| JJ
as  ||| S:884 E:887 ||| IN
sample  ||| S:887 E:894 ||| NN
batches ||| S:894 E:901 ||| NNS
,  ||| S:901 E:903 ||| ,
patient  ||| S:903 E:911 ||| JJ
ages ||| S:911 E:915 ||| NNS
,  ||| S:915 E:917 ||| ,
and  ||| S:917 E:921 ||| CC
tumor  ||| S:921 E:927 ||| NN
stages  ||| S:927 E:934 ||| NNS
further  ||| S:934 E:942 ||| RBR
confound  ||| S:942 E:951 ||| JJ
or  ||| S:951 E:954 ||| CC
suppress  ||| S:954 E:963 ||| VB
the  ||| S:963 E:967 ||| DT
identification  ||| S:967 E:982 ||| NN
of  ||| S:982 E:985 ||| IN
relevant  ||| S:985 E:994 ||| JJ
genes ||| S:994 E:999 ||| NNS
,  ||| S:999 E:1001 ||| ,
and  ||| S:1001 E:1005 ||| CC
thus  ||| S:1005 E:1010 ||| RB
the  ||| S:1010 E:1014 ||| DT
biological  ||| S:1014 E:1025 ||| JJ
functions  ||| S:1025 E:1035 ||| NNS
and  ||| S:1035 E:1039 ||| CC
disease  ||| S:1039 E:1047 ||| NN
mechanisms ||| S:1047 E:1057 ||| NNS
.  ||| S:1057 E:1059 ||| .
To  ||| S:1059 E:1062 ||| TO
address  ||| S:1062 E:1070 ||| VB
these  ||| S:1070 E:1076 ||| DT
issues ||| S:1076 E:1082 ||| NNS
,  ||| S:1082 E:1084 ||| ,
herein  ||| S:1084 E:1091 ||| VBD
we  ||| S:1091 E:1094 ||| PRP
propose  ||| S:1094 E:1102 ||| VBP
an  ||| S:1102 E:1105 ||| DT
analysis  ||| S:1105 E:1114 ||| NN
procedure  ||| S:1114 E:1124 ||| NN
designed  ||| S:1124 E:1133 ||| VBN
to  ||| S:1133 E:1136 ||| TO
reduce  ||| S:1136 E:1143 ||| VB
suppression  ||| S:1143 E:1155 ||| JJ
effect  ||| S:1155 E:1162 ||| NN
by  ||| S:1162 E:1165 ||| IN
focusing  ||| S:1165 E:1174 ||| VBG
on  ||| S:1174 E:1177 ||| IN
a  ||| S:1177 E:1179 ||| DT
specific  ||| S:1179 E:1188 ||| JJ
chemotherapeutic  ||| S:1188 E:1205 ||| JJ
treatment ||| S:1205 E:1214 ||| NN
,  ||| S:1214 E:1216 ||| ,
and  ||| S:1216 E:1220 ||| CC
to  ||| S:1220 E:1223 ||| TO
remove  ||| S:1223 E:1230 ||| VB
confounding  ||| S:1230 E:1242 ||| JJ
effects  ||| S:1242 E:1250 ||| NNS
such  ||| S:1250 E:1255 ||| JJ
as  ||| S:1255 E:1258 ||| IN
batch  ||| S:1258 E:1264 ||| NN
effect ||| S:1264 E:1270 ||| NN
,  ||| S:1270 E:1272 ||| ,
patient ||| S:1272 E:1279 ||| NN
's  ||| S:1279 E:1282 ||| POS
age ||| S:1282 E:1285 ||| NN
,  ||| S:1285 E:1287 ||| ,
and  ||| S:1287 E:1291 ||| CC
tumor  ||| S:1291 E:1297 ||| NN
stages ||| S:1297 E:1303 ||| NNS
.  ||| S:1303 E:1305 ||| .
The  ||| S:1305 E:1309 ||| DT
proposed  ||| S:1309 E:1318 ||| JJ
procedure  ||| S:1318 E:1328 ||| NN
starts  ||| S:1328 E:1335 ||| VBZ
with  ||| S:1335 E:1340 ||| IN
a  ||| S:1340 E:1342 ||| DT
batch  ||| S:1342 E:1348 ||| NN
effect  ||| S:1348 E:1355 ||| NN
adjustment ||| S:1355 E:1365 ||| NN
,  ||| S:1365 E:1367 ||| ,
followed  ||| S:1367 E:1376 ||| VBN
by  ||| S:1376 E:1379 ||| IN
a  ||| S:1379 E:1381 ||| DT
rigorous  ||| S:1381 E:1390 ||| JJ
sample  ||| S:1390 E:1397 ||| NN
selection  ||| S:1397 E:1407 ||| NN
process ||| S:1407 E:1414 ||| NN
.  ||| S:1414 E:1416 ||| .
Then ||| S:1416 E:1420 ||| RB
,  ||| S:1420 E:1422 ||| ,
the  ||| S:1422 E:1426 ||| DT
gene  ||| S:1426 E:1431 ||| NN
expression ||| S:1431 E:1441 ||| NN
,  ||| S:1441 E:1443 ||| ,
copy  ||| S:1443 E:1448 ||| NN
number ||| S:1448 E:1454 ||| NN
,  ||| S:1454 E:1456 ||| ,
and  ||| S:1456 E:1460 ||| CC
methylation  ||| S:1460 E:1472 ||| JJ
profiles  ||| S:1472 E:1481 ||| NNS
from  ||| S:1481 E:1486 ||| IN
the  ||| S:1486 E:1490 ||| DT
TCGA  ||| S:1490 E:1495 ||| NNP
ovarian  ||| S:1495 E:1503 ||| JJ
cancer  ||| S:1503 E:1510 ||| NN
dataset  ||| S:1510 E:1518 ||| NNS
are  ||| S:1518 E:1522 ||| VBP
analyzed  ||| S:1522 E:1531 ||| VBN
using  ||| S:1531 E:1537 ||| VBG
a  ||| S:1537 E:1539 ||| DT
semi-supervised  ||| S:1539 E:1555 ||| JJ
clustering  ||| S:1555 E:1566 ||| JJ
method  ||| S:1566 E:1573 ||| NN
combined  ||| S:1573 E:1582 ||| VBN
with  ||| S:1582 E:1587 ||| IN
a  ||| S:1587 E:1589 ||| DT
novel  ||| S:1589 E:1595 ||| NN
scoring  ||| S:1595 E:1603 ||| NN
function ||| S:1603 E:1611 ||| NN
.  ||| S:1611 E:1613 ||| .
As  ||| S:1613 E:1616 ||| IN
a  ||| S:1616 E:1618 ||| DT
result ||| S:1618 E:1624 ||| NN
,  ||| S:1624 E:1626 ||| ,
two  ||| S:1626 E:1630 ||| CD
molecular  ||| S:1630 E:1640 ||| JJ
classifications ||| S:1640 E:1655 ||| NNS
,  ||| S:1655 E:1657 ||| ,
one  ||| S:1657 E:1661 ||| CD
with  ||| S:1661 E:1666 ||| IN
poor  ||| S:1666 E:1671 ||| JJ
copy  ||| S:1671 E:1676 ||| NN
number  ||| S:1676 E:1683 ||| NN
profiles  ||| S:1683 E:1692 ||| NNS
and  ||| S:1692 E:1696 ||| CC
one  ||| S:1696 E:1700 ||| CD
with  ||| S:1700 E:1705 ||| IN
poor  ||| S:1705 E:1710 ||| JJ
methylation  ||| S:1710 E:1722 ||| JJ
profiles ||| S:1722 E:1730 ||| NNS
,  ||| S:1730 E:1732 ||| ,
enriched  ||| S:1732 E:1741 ||| VBG
with  ||| S:1741 E:1746 ||| IN
unfavorable  ||| S:1746 E:1758 ||| JJ
scores  ||| S:1758 E:1765 ||| NNS
are  ||| S:1765 E:1769 ||| VBP
identified ||| S:1769 E:1779 ||| VBN
.  ||| S:1779 E:1781 ||| .
Compared  ||| S:1781 E:1790 ||| VBN
with  ||| S:1790 E:1795 ||| IN
the  ||| S:1795 E:1799 ||| DT
samples  ||| S:1799 E:1807 ||| JJ
enriched  ||| S:1807 E:1816 ||| NN
with  ||| S:1816 E:1821 ||| IN
favorable  ||| S:1821 E:1831 ||| JJ
scores ||| S:1831 E:1837 ||| NNS
,  ||| S:1837 E:1839 ||| ,
these  ||| S:1839 E:1845 ||| DT
two  ||| S:1845 E:1849 ||| CD
classifications  ||| S:1849 E:1865 ||| NNS
exhibit  ||| S:1865 E:1873 ||| VBP
poor  ||| S:1873 E:1878 ||| JJ
progression-free  ||| S:1878 E:1895 ||| JJ
survival  ||| S:1895 E:1904 ||| NN
( ||| S:1904 E:1905 ||| -LRB-
PFS ||| S:1905 E:1908 ||| NNP
)  ||| S:1908 E:1910 ||| -RRB-
and  ||| S:1910 E:1914 ||| CC
might  ||| S:1914 E:1920 ||| MD
be  ||| S:1920 E:1923 ||| VB
associated  ||| S:1923 E:1934 ||| VBN
with  ||| S:1934 E:1939 ||| IN
poor  ||| S:1939 E:1944 ||| JJ
chemotherapy  ||| S:1944 E:1957 ||| JJ
response  ||| S:1957 E:1966 ||| NN
specifically  ||| S:1966 E:1979 ||| RB
to  ||| S:1979 E:1982 ||| TO
the  ||| S:1982 E:1986 ||| DT
combination  ||| S:1986 E:1998 ||| NN
of  ||| S:1998 E:2001 ||| IN
paclitaxel  ||| S:2001 E:2012 ||| NN
and  ||| S:2012 E:2016 ||| CC
carboplatin ||| S:2016 E:2027 ||| NN
.  ||| S:2027 E:2029 ||| .
Significant  ||| S:2029 E:2041 ||| JJ
genes  ||| S:2041 E:2047 ||| NNS
and  ||| S:2047 E:2051 ||| CC
biological  ||| S:2051 E:2062 ||| JJ
processes  ||| S:2062 E:2072 ||| NNS
are  ||| S:2072 E:2076 ||| VBP
detected  ||| S:2076 E:2085 ||| VBN
subsequently  ||| S:2085 E:2098 ||| RB
using  ||| S:2098 E:2104 ||| VBG
classical  ||| S:2104 E:2114 ||| JJ
statistical  ||| S:2114 E:2126 ||| JJ
approaches  ||| S:2126 E:2137 ||| NNS
and  ||| S:2137 E:2141 ||| CC
enrichment  ||| S:2141 E:2152 ||| JJ
analysis ||| S:2152 E:2160 ||| NN
.  ||| S:2160 E:2162 ||| .
The  ||| S:2162 E:2166 ||| DT
proposed  ||| S:2166 E:2175 ||| JJ
procedure  ||| S:2175 E:2185 ||| NN
for  ||| S:2185 E:2189 ||| IN
the  ||| S:2189 E:2193 ||| DT
reduction  ||| S:2193 E:2203 ||| NN
of  ||| S:2203 E:2206 ||| IN
confounding  ||| S:2206 E:2218 ||| NN
and  ||| S:2218 E:2222 ||| CC
suppression  ||| S:2222 E:2234 ||| JJ
effects  ||| S:2234 E:2242 ||| NNS
and  ||| S:2242 E:2246 ||| CC
the  ||| S:2246 E:2250 ||| DT
semi-supervised  ||| S:2250 E:2266 ||| JJ
clustering  ||| S:2266 E:2277 ||| JJ
method  ||| S:2277 E:2284 ||| NN
are  ||| S:2284 E:2288 ||| VBP
essential  ||| S:2288 E:2298 ||| JJ
steps  ||| S:2298 E:2304 ||| NNS
to  ||| S:2304 E:2307 ||| TO
identify  ||| S:2307 E:2316 ||| VB
genes  ||| S:2316 E:2322 ||| NNS
associated  ||| S:2322 E:2333 ||| VBN
with  ||| S:2333 E:2338 ||| IN
the  ||| S:2338 E:2342 ||| DT
chemotherapeutic  ||| S:2342 E:2359 ||| JJ
response ||| S:2359 E:2367 ||| NN
.  ||| S:2367 E:2369 ||| .
